Weight-Loss Jab Plus Antibody: Less Lean Mass Lost
Graded Moderate — a double-blind trial with random assignment of 975 people over 26 to 52 weeks, but it measured body composition, not strength or health.
- Design
- Randomized controlled trial
- Participants
- 975
- Duration
- 6 months
- Funding
- Regeneron Pharmaceuticals, Inc.
Trevogrumab reduced lean mass loss during semaglutide treatment, while adding garetosmab caused poor tolerability.
Fast weight loss on drugs like semaglutide also strips away a lot of muscle, the researchers write. Adding an antibody called trevogrumab slowed that loss. The antibody blocks myostatin, a natural signal in the body that holds back muscle growth.
At 60 sites in the US, adults with obesity took weekly semaglutide for half a year. They were chosen at random to also get trevogrumab, trevogrumab plus a second antibody called garetosmab, or a dummy treatment. With the dummy, lean mass, mostly muscle, shrank by 6.6 percent. With trevogrumab, the loss was about 3 percentage points smaller. In a second, year-long part of the study, the higher dose showed the same effect.
The two-antibody combination also melted away more fat, but people tolerated it poorly. Almost a third stopped treatment, and many had muscle cramps. Two people died, and the researchers found no link to the treatment. Whether the preserved lean mass means more strength is not yet clear: the trial measured body composition, not function.
Conflict of Interest Disclosure: Regeneron, which makes both antibodies, funded the trial, and several authors are its employees and shareholders.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.
